TIOFOSFAMID (Thiophosphamidum).

     N, N ', N "- Three (ethylene) - triamid tiofosfornoy acid or N, N', N" - Trietilenimintiofosfamid.

     Synonyms : TioTEF, Deltespamine, Oncotepal, Thiofosyl, Thiotepa, Thio-TEPA, Tespamin, Tifosyl, TSPA.

     The white crystalline powder (dried) or plates. The easily soluble in water. Aqueous solutions nestoyki and not sterilized as easily gidrolizuyutsya.

     Tiofosfamid has cytostatic effect and oppressing proliferiruyuschey development, including malignant fabric. In the mechanism of action of these compounds play an important role breach of the exchange of nucleic acids and fathers blockade of cell division.

     Applied tiofosfamid with ovarian cancer (if neglected forms for pre-treatment, aftercare period), breast cancer (in recurrence and metastases, Inoperable Tumors, for the treatment of pleurisy in aftercare period) and some other tumors (mesothelioma, retinoblastoma, a cancer urine bubble).

     Application tiofosfamida helps reduce recurrence and metastases after radical mastektomii, in the treatment of breast cancer, increases the percentage bezretsidivnogo during the process.

     An tiofosfamida with chronic lymphoblastic and chronic mieloleykoze (in the form leykemicheskoy), chlamydia, retikulosarkome, limfosarkomatoze.

     The drug is available in hermetically ukuporennyh bottles containing 0.01 or 0.02 g (10 or 20 mg) drug as a powder or tablets. Solutions prepared immediately before use : type of syringe in a bottle five or 10 ml of sterile water for injection.

     Tiofosfamid can be injected intramuscularly, intravenously, vnutriarterialno and cavities (vnutriplevralno and vnutribryushinno). It may also direct entry into the tumor.

     Dose and duration of treatment should be strongly depending on the nature of the disease, the general condition of the patient, treatment and endurance drug.

     Patients weighing 60 to 70 kg designate tiofosfamid usually occasional dose of 0,015 g (15 mg); Patients with haematopoietic system can be sustained at the beginning of treatment to be 20 mg; Patients with low weight and tend to radiation designate 10 mg. The preparation to enter through the day (3 times a week). At treatment 0,15 - 0,2 g (150-200 mg).

     During treatment systematically studied blood. Treatment drop in the number of leukocyte reduction of up to 3 x 10 9 / L, and platelets 100 x 10 / l. Hematology studies conducted over 2 to 3 weeks after treatment, as well as reducing the number of cells may continue after cessation of the drug.

     With effect from the time the first course of treatment or recurrence, a treatment repeated at intervals of 1, 5, 3 months; In the course of using 0,15 - 0,2 g of the drug (control Haematology Research). In some cases it is recommended to further effect a month after the first treatment tiofosfamidom, additional treatment with 0.1 grams of the drug on the course. Additional courses are designated for the restoration to the rules of leukocyte and platelets.

     Tiofosfamid could be introduced in high-dose intravenous-40 60 1 mg once a week or 80-100 1 mg every 3 to 4 weeks. Heading dose that is 0.15 - 0.25 g.

     With the effusion and seroznyh cavity (cirrhosis and pleurisy in the ovary cancer, pleurisy with breast cancer, etc.) shows a tiofosfamida intraoral. Diluted give abdominal and chest cavity after removal exudation dose of 20 to 40 mg in 5 to 10 ml isotonic sodium chloride solution 1 to 2 times a week. Intraoral introduction can be combined with intramuscular. The total dose of a drug is determined by blood indicators.

     When thyroid cancer tiofosfamid enter via catheters placed in the upper neck artery. After each catheter impose daily 5 mg drug; In the course of 40-95 mg.

     To cure haematopoietic system appoint tiofosfamid intramuscularly or intravenously. Dose and duration of treatment should be individualized depending on the effectiveness of the drug. Typically, in the early days of entering adults every day or every other day for 10 mg, and then, depending on the impact on the number of cells and platelets every 1 - 2 - 3 - 4 - 5 days; Subsequent injections are one every 7 to 14 days. The total dose of treatment ranged from 0.1 to 0.3 g (100-300 mg).

     When treating tiofosfamidom need at least a day to control the content of leukocyte and 2 times a week - of platelets. Total blood to 1 week.

     When leukemia treatment is interrupted if the number of leukocyte quickly reduced to 100 x 10 9 / L-80 x 10 9 / L; For further lengthened the interval between injections; While the number of white, 60 x 10 x 40 9 10 9 / L, a drug stop, given that during the two weeks-Z may be the influence of the drug on krovetvorennya.

     When chlamydia and retikulosarkomatoze tiofosfamidam treatment can begin at normal or even slightly reduced the number of cells (but not less than 4 x 10 9 / L). Treatment with these diseases drop in the number of leukocyte reduction to 3 x 109 / l, and platelets 100 x 10 9 / L.

     Application tiofosfamida with moderate radiation, thrombocytopenia or anaemia should be combined with blood transfusions or leykotsitnoy, trombotsitnoy, eritrotsitnoy estate.

     In case of heavy oppression kostnomozgovogo blood during treatment tiofosfamidom, immediately terminate a drug, blood transfusion or designate leykotsitnoy and trombotsitnoy estate, as well as stimulants blood (leucogen, pentoksil, nukleinat sodium, vitamins). To prevent secondary infection impose penicillin.

     In the case of diarrhea, and increased sensitivity to tiofosfamidu reduce the dose or increase the interval between injections.

     Tiofosfamid contraindications for the general condition and cachexia, with the number of cells in the peripheral blood below 4 x 10 9 / L and platelets less than 150 x 10 9 / L, immediately after radiation therapy (a tiofosfamida allowed one month after the end of radiation therapy with the restoration of paintings blood).

     Contraindications to the use tiofosfamida with chronic leukaemia are aleykicheskie form of the disease (leukocyte number less than 20 x 10 9 / L), thrombocytopenia (less than 200 x 10 9 / L), expressed anemia (erythrocyte number below 3 x 10 12 / L).

     In some cases it could be in the number of platelets tiofosfamida below 200 x 10 9 / L but above 100 ? 10 9 / L, if both make blood transfusions or trombotsitnoy estate. In anemia, to treat tiofosfamidom, a antianemicheskuyu therapy with blood transfusions and the introduction eritrotsitnoy estate.

     Product : powder or pill bottles in a hermetically ukuporennyh to 0,01 - 0,02 g (for injection solutions-1 pill in vial).

     Storage : List A. In the dark place at a temperature no higher than  +10 C.

Materials allowed to copy only with the active hyperlink to the handbook of medicines